文献速递甲状腺疾病

仑伐替尼与索拉非尼作为放射性碘难治性进展性分化型甲状腺癌一线治疗的比较:多中心回顾性队列研究的真实世界结局

Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
PubMed 文献 · Thyroid · 2022-05-17

这项多中心回顾性队列研究纳入136例进展性远处转移或局部晚期、放射性碘难治性分化型甲状腺癌或低分化甲状腺癌患者,比较一线索拉非尼(80例)与仑伐替尼(56例)的疗效与安全性。仑伐替尼组中位无进展生存期35.3个月,索拉非尼组13.3个月(p=0.001);校正后风险比0.34(95%CI 0.19-0.60,p<0.001)。仑伐替尼组3-4级高血压和蛋白尿更常见,索拉非尼组手足皮肤反应更常见。

要点

  • 仑伐替尼组中位无进展生存期35.3个月,索拉非尼组13.3个月(p=0.001)。
  • 校正后仑伐替尼较索拉非尼的无进展生存期风险比0.34(95%CI 0.19-0.60,p<0.001)。
  • 仑伐替尼组3-4级高血压和蛋白尿更常见,索拉非尼组手足皮肤反应更常见。

核心结论

  • 在亚洲患者中,一线仑伐替尼治疗转移性或局部晚期、进展性、放射性碘难治性分化型甲状腺癌或低分化甲状腺癌较索拉非尼与更长的无进展生存期相关。
  • 仑伐替尼治疗后严重高血压和蛋白尿较索拉非尼治疗后更常见。

研究设计与样本

  • 多中心回顾性队列研究,纳入136例进展性远处转移或局部晚期、进展性、放射性碘难治性分化型甲状腺癌或低分化甲状腺癌患者,接受一线索拉非尼或仑伐替尼治疗。
  • 索拉非尼组80例,仑伐替尼组56例;患者中位年龄68岁,男性占35%(47/136)。
  • 主要结局为无进展生存期,同时评估客观缓解率、疾病控制率、临床获益率及安全性。

主要发现

  • 索拉非尼组中位无进展生存期13.3个月(95%CI 9.9-18.1个月),仑伐替尼组35.3个月(95%CI 18.2个月至未报告上限,因中位未达到)(p=0.001)。
  • 校正年龄、性别、病理、疾病相关症状、仅肺转移、累积放射性碘剂量、自诊断时间、治疗持续时间及靶病灶最长径后,仑伐替尼组较索拉非尼组无进展生存期显著延长(风险比=0.34,95%CI 0.19-0.60,p<0.001)。
  • 部分缓解率索拉非尼组24%,仑伐替尼组59%(p<0.001)。
  • 仑伐替尼组较索拉非尼组更常见的3-4级不良事件为高血压(16%,9/56 vs 1%,1/80,p=0.002)和蛋白尿(32%,18/56 vs 0%,p<0.001)。
  • 索拉非尼组较仑伐替尼组更常见的3-4级不良事件为手足皮肤反应(24%,19/80 vs 4%,2/56,p=0.001)。

关键数值与推荐

  • 索拉非尼组中位无进展生存期13.3个月(95%CI 9.9-18.1个月)vs 仑伐替尼组35.3个月(95%CI 18.2个月至未报告上限)(p=0.001)。
  • 校正后风险比=0.34(95%CI 0.19-0.60,p<0.001),仑伐替尼组较索拉非尼组无进展生存期延长。
  • 部分缓解率索拉非尼组24% vs 仑伐替尼组59%(p<0.001)。
  • 3-4级高血压:仑伐替尼组16%(9/56)vs 索拉非尼组1%(1/80)(p=0.002)。
  • 3-4级蛋白尿:仑伐替尼组32%(18/56)vs 索拉非尼组0%(p<0.001);3-4级手足皮肤反应:索拉非尼组24%(19/80)vs 仑伐替尼组4%(2/56)(p=0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Sorafenib and lenvatinib have been widely adopted to treat radioactive iodine (RAI)-refractory differentiated thyroid carcinoma (DTC). However, limited data exist regarding a direct comparison of these tyrosine kinase inhibitors (TKIs). We aimed to evaluate the clinical efficacy and safety of two TKIs as first-line therapy in patients with distant metastatic or locally advanced, progressive, RAI-refractory DTC in real-world practice. Methods: In this multicenter, retrospective cohort study, we evaluated 136 patients with progressive distant metastatic or locally advanced, progressive, RAI-refractory DTC or poorly differentiated thyroid carcinoma (PDTC) who received first-line sorafenib or lenvatinib treatment. The primary outcome was progression-free survival (PFS). We also evaluated the objective response rate, disease-control rate, clinical benefit rate, and safety. Results: The median age of the patients was 68 years, and 35% (47/136) were male. Eighty and fifty-six patients were included in the sorafenib and lenvatinib groups, respectively. The median PFS was 13.3 months [95% confidence interval, CI, 9.9-18.1 months] in the sorafenib group and 35.3 months [CI, 18.2 months to upper limit not reported as the median was not reached] in the lenvatinib group (p = 0.001). A significantly prolonged PFS was observed in the lenvatinib group (compared with the sorafenib group) after adjusting for age, sex, pathology, disease-related symptom, lung-only metastasis, cumulative RAI dose, time from diagnosis, treatment duration, and longest diameter of the target lesion (hazard ratio = 0.34, CI, 0.19-0.60, p < 0.001). The partial response rate was 24% and 59% in the sorafenib and lenvatinib groups, respectively (p < 0.001). More common grade 3-4 adverse events were hypertension (16%, 9/56 vs. 1%, 1/80, p = 0.002) and proteinuria (32%, 18/56 vs. 0%, p < 0.001) in the lenvatinib group, and hand-foot skin reaction (24%, 19/80 vs. 4%, 2/56, p = 0.001) in the sorafenib group. Conclusion: In our study of Asian patients, first-line lenvatinib treatment of metastatic or locally advanced, progressive, RAI-refractory DTC or PDTC was associated with a longer PFS compared with sorafenib. However, severe hypertension and proteinuria were observed more frequently after lenvatinib treatment than after sorafenib treatment.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Kim M, Jin M, Jeon MJ, et al. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study. Thyroid. 2022. PMID: 35443825. doi:10.1089/thy.2022.0054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。